(Q48220006)

9 February 2018

title

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. (English)

1 reference

9 February 2018

0 references

8

James P Allison

0 references

Darell D. Bigner

9

object named as

Darell D Bigner

1 reference

9 February 2018

Peter E Fecci

1

1 reference

9 February 2018

Hidenobu Ochiai

2

1 reference

9 February 2018

Duane A Mitchell

3

1 reference

9 February 2018

Peter M Grossi

4

1 reference

9 February 2018

Alison E Sweeney

5

1 reference

9 February 2018

Gary E Archer

6

1 reference

9 February 2018

Thomas Cummings

7

1 reference

9 February 2018

John H Sampson

10

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 April 2007

1 reference

9 February 2018

published in

Clinical Cancer Research

1 reference

9 February 2018

volume

13

1 reference

9 February 2018

page(s)

2158-2167

1 reference

9 February 2018

issue

7

1 reference

9 February 2018

CTLA-4 can function as a negative regulator of T cell activation

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/1074-7613(94)90071-X

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

CTLA-4: a negative regulator of autoimmune disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Immune defects observed in patients with primary malignant brain tumors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

The emerging role of CTLA-4 as an immune attenuator

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

A new member of the immunoglobulin superfamily--CTLA-4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2070

Identifiers

DOI

10.1158/1078-0432.CCR-06-2070

1 reference

9 February 2018

PubMed ID

17404100

1 reference

9 February 2018